<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; arbitrary</title>
	<atom:link href="http://www.tapanray.in/tag/arbitrary/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Innovative ‘Medicines Too Damn Expensive’: Health Risk For Billions of People</title>
		<link>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people</link>
		<comments>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/#comments</comments>
		<pubDate>Mon, 18 Mar 2019 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ailments]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[billions]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[damn]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[millions]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9448</guid>
		<description><![CDATA[Most ‘medicines are too damn expensive. And a key part of the problem is the lack of consistent information about drug pricing. It’s not often that the Trump administration and the anti-poverty NGO Oxfam find themselves singing from the same &#8230; <a href="http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Déjà Vu In Pharma Industry</title>
		<link>http://www.tapanray.in/deja-vu-in-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deja-vu-in-pharma-industry</link>
		<comments>http://www.tapanray.in/deja-vu-in-pharma-industry/#comments</comments>
		<pubDate>Mon, 12 Sep 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Ananth]]></category>
		<category><![CDATA[apocalypse]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Déjà Vu]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EiPen]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Kumar]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharma Industry]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relief]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7806</guid>
		<description><![CDATA[It’s happening in the West, and is equally widespread in the Eastern part of the globe too, though in different ways and forms, as both the national and international media have been reporting, consistently. The phenomenon is all pervasive, and &#8230; <a href="http://www.tapanray.in/deja-vu-in-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deja-vu-in-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Next Frontier: Frugal Innovation For High-Tech Drugs</title>
		<link>http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-next-frontier-frugal-innovation-for-high-tech-drugs</link>
		<comments>http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/#comments</comments>
		<pubDate>Mon, 30 May 2016 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[facade]]></category>
		<category><![CDATA[Frugal]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[saving]]></category>
		<category><![CDATA[Stemcentrx]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tech]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7655</guid>
		<description><![CDATA[Should drug innovation models remain as expensive as what these are claimed to be now by the global pharma industry, in general? Finding a credible, appropriately quantifiable, and generally acceptable answer to this question is critical. It won’t, then, just &#8230; <a href="http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arbitrary Pricing of Essential Drugs Invites State Intervention</title>
		<link>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=arbitrary-pricing-of-essential-drugs-invites-state-intervention</link>
		<comments>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/#comments</comments>
		<pubDate>Mon, 23 May 2016 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[premium]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[winner]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7644</guid>
		<description><![CDATA[Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. &#8230; <a href="http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Expensive Is Drug Innovation?</title>
		<link>http://www.tapanray.in/how-expensive-is-drug-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-expensive-is-drug-innovation</link>
		<comments>http://www.tapanray.in/how-expensive-is-drug-innovation/#comments</comments>
		<pubDate>Mon, 16 May 2016 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affairs]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[goods]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tufts Centre]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7637</guid>
		<description><![CDATA[High prices for patented drugs are quite often attributed to the exorbitant cost of drug innovation, by the global pharma players. This argument is played, replayed again, again… and again by them, in various ways and forms, especially when many &#8230; <a href="http://www.tapanray.in/how-expensive-is-drug-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-expensive-is-drug-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
